{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T22:42:28Z","timestamp":1793313748418,"version":"4.5.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2010,6,22]],"date-time":"2010-06-22T00:00:00Z","timestamp":1277164800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Neurol Neurosci Rep"],"published-print":{"date-parts":[[2010,9]]},"DOI":"10.1007\/s11910-010-0129-z","type":"journal-article","created":{"date-parts":[[2010,6,21]],"date-time":"2010-06-21T07:24:40Z","timestamp":1277105080000},"page":"338-344","source":"Crossref","is-referenced-by-count":31,"title":["An Update on the Neurologic Applications of Botulinum Toxins"],"prefix":"10.1007","volume":"10","author":[{"given":"Virgilio Gerald H.","family":"Evidente","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles H.","family":"Adler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,6,22]]},"reference":[{"key":"129_CR1","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1006\/scel.1994.1028","volume":"5","author":"G Schiavo","year":"1994","unstructured":"Schiavo G, Rossetoo O, Montecucco C. Clostridial neurotoxins as tools to investigate the molecular events of neurotransmitter release. Semin Cell Biol 1994, 5:221\u2013229.","journal-title":"Semin Cell Biol"},{"key":"129_CR2","doi-asserted-by":"crossref","first-page":"10461","DOI":"10.1016\/S0021-9258(19)85105-0","volume":"260","author":"V Sathyamurthy","year":"1985","unstructured":"Sathyamurthy V, Dasgupta BR: Separation, purification, partial characterization and comparison of the heavy and light chains of botulinum neurotoxin types A, B and E. J Biol Chem 1985, 260:10461\u201310466.","journal-title":"J Biol Chem"},{"key":"129_CR3","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/0163-7258(82)90061-4","volume":"19","author":"G Sakaguchi","year":"1982","unstructured":"Sakaguchi G: Clostridium botulinum toxins. Pharmacol Ther 1982, 19:165\u2013194.","journal-title":"Clostridium botulinum toxins. Pharmacol Ther"},{"key":"129_CR4","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1159\/000060684","volume":"30","author":"O Rossetto","year":"2002","unstructured":"Rossetto O, Seveso M, Caccin P, et al.: Botulinum neurotoxins are metalloproteases specific for SNARE proteins involved in neuroexocytosis. Curr Probl Dermatol 2002, 30:117\u2013125.","journal-title":"Curr Probl Dermatol"},{"issue":"Suppl 2","key":"129_CR5","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1468-1331.2009.02879.x","volume":"16","author":"J Frevert","year":"2009","unstructured":"Frevert J: Xeomin: an innovative new botulinum toxin type A. Eur J Neurol 2009, 16(Suppl 2):11\u201313.","journal-title":"Eur J Neurol"},{"key":"129_CR6","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1099\/mic.0.28421-0","volume":"151","author":"JC Lee","year":"2005","unstructured":"Lee JC, Yokota K, Arimitsu H, et al.: Production of anti-neurotoxin antibody is enhanced by two subcomponents, HA1 and HA3b of Clostridium botulinum type B 16S toxin-haemagglutinin. Microbiology 2005, 151:3739\u20133747.","journal-title":"Microbiology"},{"key":"129_CR7","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Simpson DM, Blitzer A, Brashear A, et al.: Assessment: botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics Assessment Subcommittee of the American Academy of Neurology. Neurology 2008, 70:1699\u20131706. This article reviews medical evidence for using BoNT for various movement disorders and suggests guidelines for using BoNT for these conditions.","DOI":"10.1212\/01.wnl.0000311389.26145.95"},{"key":"129_CR8","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1212\/WNL.40.8.1213","volume":"40","author":"P Greene","year":"1990","unstructured":"Greene P, Kang U, Fahn S, et al.: Double-blind, placebo-controlled trial of botulinum toxin injections for the treatment of spasmodic torticollis. Neurology 1990, 40:1213\u20131218.","journal-title":"Neurology"},{"key":"129_CR9","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1136\/jnnp.64.1.13","volume":"64","author":"W Poewe","year":"1998","unstructured":"Poewe W, Deuschl G, Nebe A, et al.: What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double blind, placebo controlled, dose ranging study using Dysport. German Dystonia Study Group. J Neurol Neurosurg Psychiatry 1998, 64:13\u201317.","journal-title":"German Dystonia Study Group. J Neurol Neurosurg Psychiatry"},{"key":"129_CR10","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1212\/WNL.46.4.1066","volume":"46","author":"JW Brans","year":"1996","unstructured":"Brans JW, Lindeboom R, Snoek JW, et al.: Botulinum toxin versus trihexyphenidyl in cervical dystonia: a prospective, randomized, double-blind controlled trial. Neurology 1996, 46:1066\u20131072.","journal-title":"Neurology"},{"key":"129_CR11","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1212\/WNL.53.7.1439","volume":"53","author":"A Brashear","year":"1999","unstructured":"Brashear A, Lew MF, Dykstra DD, et al.: Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia. Neurology 1999, 53:1439\u20131446.","journal-title":"Neurology"},{"key":"129_CR12","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1212\/WNL.53.7.1431","volume":"53","author":"MF Brin","year":"1999","unstructured":"Brin MF, Lew MF, Adler CH, et al.: Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia. Neurology 1999, 53:1431\u20131438.","journal-title":"Neurology"},{"key":"129_CR13","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1002\/mds.20403","volume":"20","author":"D Truong","year":"2005","unstructured":"Truong D, Duane DD, Jankovic J, et al.: Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study. Mov Disord 2005, 20:783\u2013791.","journal-title":"Mov Disord"},{"key":"129_CR14","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1212\/WNL.49.3.701","volume":"49","author":"MF Lew","year":"1997","unstructured":"Lew MF, Adornato BT, Duane DD, et al.: Botulinum toxin type B: a double-blind, placebo-controlled, safety and efficacy study in cervical dystonia. Neurology 1997, 49:701\u2013707.","journal-title":"Neurology"},{"key":"129_CR15","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1002\/mds.21724","volume":"23","author":"EJ Pappert","year":"2008","unstructured":"Pappert EJ, Germanson T; for the Myobloc\/Neurobloc European Cervical Dystonia Study Group: Botulinum toxin type B vs type A in toxin-na\u00efve patients with cervical dystonia: randomized, double-blind, noninferiority trial. Mov Disord 2008, 23:510\u2013517.","journal-title":"Mov Disord"},{"key":"129_CR16","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/j.clinthera.2007.07.020","volume":"29","author":"MA Chapman","year":"2007","unstructured":"Chapman MA, Barron R, Tanis DC, et al.: Comparison of botulinum neurotoxin preparations for the treatment of cervical dystonia. Clin Ther 2007, 29:1325\u20131337.","journal-title":"Clin Ther"},{"key":"129_CR17","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/BF03033933","volume":"9","author":"J Jankovic","year":"2006","unstructured":"Jankovic J: Botulinum therapy for cervical dystonia. Neurotox Res 2006, 9:145\u2013148.","journal-title":"Neurotox Res"},{"key":"129_CR18","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1007\/s00415-005-0774-3","volume":"252","author":"D Dressler","year":"2005","unstructured":"Dressler D, Bigalke H: Botulinum toxin type B de novo therapy of cervical dystonia: frequency of antibody induced therapy failure. J Neurol 2005, 252:904\u2013907.","journal-title":"J Neurol"},{"key":"129_CR19","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1212\/01.WNL.0000055087.96356.BB","volume":"60","author":"J Jankovic","year":"2003","unstructured":"Jankovic J, Vuong KD, Ahsan J: Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia. Neurology 2003, 60:1186\u20131188.","journal-title":"Neurology"},{"key":"129_CR20","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s00702-005-0323-3","volume":"113","author":"P Roggenkamper","year":"2006","unstructured":"Roggenkamper P, Jost WH, Bihari K, et al.: Efficacy and safety of a new botulinum toxin type A free of complexing proteins in the treatment of blepharospasm. J Neural Transm 2006, 113:303\u2013312.","journal-title":"J Neural Transm"},{"key":"129_CR21","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/BF00941758","volume":"235","author":"Z Nussgens","year":"1997","unstructured":"Nussgens Z, Roggenkamper P: Comparison of two botulinum toxin preparations in the treatment of essential blepharospasm. Graefes Arch Clin Exp Ophthalmol 1997, 235:197\u2013199.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"129_CR22","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.parkreldis.2007.11.003","volume":"14","author":"D Truong","year":"2008","unstructured":"Truong D, Comella C, Fernandez HH, Ondo WG: On behalf of the Dysport Benign Essential Blepharospasm Study Group. Efficacy and safety of purified botulinum toxin type A (Dysport) for the treatment of benign essential blepharospasm: a randomized, placebo-controlled, phase II trial. Parkinsonism Relat Disord 2008, 14:407\u2013414.","journal-title":"Parkinsonism Relat Disord"},{"key":"129_CR23","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1002\/mus.880150909","volume":"15","author":"DM Yokimura","year":"1992","unstructured":"Yokimura DM, Aminoff MJ, Tami TA, Scott AB: Treatment of hemifacial spasm with botulinum toxin. Muscle Nerve 1992, 15:1045\u20131049.","journal-title":"Muscle Nerve"},{"key":"129_CR24","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1002\/mds.870120627","volume":"12","author":"C Sampaio","year":"1997","unstructured":"Sampaio C, Ferreira JJ, Simoes F, et al.: DYSBOT: a single-blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A\u2014Dysport and Botox\u2014assuming a ratio of 4:1. Mov Disord 1997, 12:1013\u20131018.","journal-title":"Mov Disord"},{"key":"129_CR25","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/01.iop.0000217382.33972.c4","volume":"22","author":"JJ Dutton","year":"2006","unstructured":"Dutton JJ, White JJ, Richard MJ: Myobloc for the treatment of benign essential blepharospasm in patients refractory to botox. Ophthal Plast Reconstr Surg 2006, 22:173\u2013177.","journal-title":"Ophthal Plast Reconstr Surg"},{"key":"129_CR26","first-page":"520","volume":"10","author":"S Badarny","year":"2008","unstructured":"Badarny S, Susel Z, Honigman S: Effectivity of Dysport in patients with blepharospasm and hemifacial spasm with experienced failure with Botox. Isr Med Assoc J 2008, 10:520\u2013522.","journal-title":"Isr Med Assoc J"},{"key":"129_CR27","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/PL00007849","volume":"249","author":"R Cakmur","year":"2002","unstructured":"Cakmur R, Ozturk V, Uzunel F, et al.: Comparison of preseptal and pretarsal injections of botulinum toxin in the treatment of blepharospasm and hemifacial spasm. J Neurol 2002, 249:64\u201368.","journal-title":"J Neurol"},{"key":"129_CR28","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1288\/00005537-199111000-00010","volume":"101","author":"N Hermanowicz","year":"1991","unstructured":"Hermanowicz N, Truong DD: Treatment of oromandibular dystonia with botulinum toxin. Laryngoscope 1991, 101:1216\u20131218.","journal-title":"Laryngoscope"},{"key":"129_CR29","first-page":"44","volume":"20","author":"XH Wan","year":"2005","unstructured":"Wan XH, Vuong KD, Jankovic J: Clinical application of botulinum toxin type B in movement disorders and autonomic symptoms. Chin Med Sci J 2005, 20:44\u201347.","journal-title":"Chin Med Sci J"},{"key":"129_CR30","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1097\/00005537-199810000-00003","volume":"108","author":"A Blitzer","year":"1998","unstructured":"Blitzer A, Brin MF, Stewart CF: Botulinum toxin management of spasmodic dysphonia (laryngeal dystonia): a 12-year experience in more than 900 patients. Laryngoscope 1998, 108:1435\u20131441.","journal-title":"Laryngoscope"},{"key":"129_CR31","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1288\/00005537-199106000-00010","volume":"101","author":"DD Truong","year":"1991","unstructured":"Truong DD, Rontal M, Roinick M, et al.: Double-blind controlled study of botulinum toxin in adductor spasmodic dysphonia. Laryngoscope 1991, 101:630\u2013634.","journal-title":"Laryngoscope"},{"key":"129_CR32","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1746-160X-5-20","volume":"5","author":"T Upile","year":"2009","unstructured":"Upile T, Elmiyeh B, Jerjes W, et al.: Unilateral versus bilateral thyroarytenoid Botulinum toxin injections in adductor spasmodic dysphonia: a prospective study. Head Face Med 2009, 5:20.","journal-title":"Head Face Med"},{"key":"129_CR33","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1002\/mds.20098","volume":"19","author":"CH Adler","year":"2004","unstructured":"Adler CH, Bansberg SF, Krein-Jones K, Hentz JG: Safety and efficacy of botulinum toxin type B (Myobloc) in adductor spasmodic dysphonia. Mov Disord 2004, 19:1075\u20131079.","journal-title":"Mov Disord"},{"key":"129_CR34","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1177\/000348940111000503","volume":"110","author":"S Bielamiowicz","year":"2001","unstructured":"Bielamiowicz S, Squire S, Bidus K, Ludlow CL: Assessment of posterior cricoarytenoid botulinum toxin injections in patients with abductor spasmodic dysphonia. Ann Otol Rhinol Laryngol 2001, 110:406\u2013412.","journal-title":"Ann Otol Rhinol Laryngol"},{"key":"129_CR35","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1136\/jnnp.2005.083170","volume":"78","author":"JJ Kruisdijk","year":"2007","unstructured":"Kruisdijk JJ, Koelman JH, Ongerboer de Visser BW, et al.: Botulinum toxin for writer\u2019s cramp: a randomized, placebo-controlled trial and 1-year follow-up. J Neurol Neurosurg Psychiatry 2007, 78:264\u2013270.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"129_CR36","first-page":"183","volume":"43","author":"R Cole","year":"1995","unstructured":"Cole R, Hallet M, Cohen LG: Double-blind trial of botulinum toxin for treatment of focal hand dystonia. Mov Disord 1995, 43:183\u2013185.","journal-title":"Mov Disord"},{"key":"129_CR37","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Simpson DM, Gracies J-M, Graham HK, et al.: Assessment: botulinum neurotoxin for the treatment of spasticity (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008, 70:1691\u20131698. This article represents the most current review of medical evidence by the American Academy of Neurology for using BoNT for the treatment of spasticity.","DOI":"10.1212\/01.wnl.0000311391.00944.c4"},{"key":"129_CR38","doi-asserted-by":"crossref","unstructured":"Kaji R, Osako Y, Suyama K, et al.: Botulinum toxin type A in post-stroke lower limb spasticity: a multicenter, double-blind, placebo-controlled trial. J Neurol 2010 Apr 1 (Epub ahead of print).","DOI":"10.1007\/s00415-010-5526-3"},{"key":"129_CR39","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1017\/S0012162206000041","volume":"48","author":"V Mall","year":"2006","unstructured":"Mall V, Heinen F, Siebel A, et al.: Treatment of adductor spasticity with BTX-A in children with CP: a randomized, double-blind, placebo-controlled study. Dev Med Child Neurol 2006, 48:10\u201313.","journal-title":"Dev Med Child Neurol"},{"key":"129_CR40","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/mds.870110306","volume":"11","author":"J Jankovic","year":"1996","unstructured":"Jankovic J, Schwartz K, Clemence W, et al.: A randomized, double-blind, placebo-controlled study to evaluate botulinum toxin type A in essential hand tremor. Mov Disord 1996, 11:250\u2013256.","journal-title":"Mov Disord"},{"key":"129_CR41","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1212\/WNL.56.11.1523","volume":"56","author":"MF Brin","year":"2001","unstructured":"Brin MF, Lyons KE, Doucette J, et al.: A randomized, double masked, controlled trial of botulinum toxin type A in essential hand tremor. Neurology 2001, 56:1523\u20131528.","journal-title":"Neurology"},{"key":"129_CR42","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1212\/WNL.45.4.822","volume":"45","author":"R Pahwa","year":"1995","unstructured":"Pahwa R, Busenbark K, Swanson-Hyland EF, et al.: Botulinum toxin treatment of essential head tremor. Neurology 1995, 45:822\u2013824.","journal-title":"Neurology"},{"key":"129_CR43","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1001\/archneur.61.9.1416","volume":"61","author":"CH Adler","year":"2004","unstructured":"Adler CH, Bansberg SF, Hentz JG, et al.: Botulinum toxin type A for treating voice tremor. Arch Neurol 2004, 61:1416\u20131420.","journal-title":"Arch Neurol"},{"key":"129_CR44","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1212\/WNL.56.5.605","volume":"56","author":"C Marras","year":"2001","unstructured":"Marras C, Andrews D, Sime E, Lang AE: Botulinum toxin for simple motor tics: a randomized, double-blind, controlled clinical trial. Neurology 2001, 56:605\u2013610.","journal-title":"Neurology"},{"key":"129_CR45","doi-asserted-by":"crossref","unstructured":"Rath JJ, Tavy DL, Wertenbroek AA, et al.: Botulinum toxin type A in simple motor tics: short-term and long-term treatment effects. Parkinsonism Relat Disord 2009, doi: 10.1016\/j.parkreldis.2009.11.011 .","DOI":"10.1016\/j.parkreldis.2009.11.011"},{"key":"129_CR46","doi-asserted-by":"crossref","unstructured":"\u2022 Naumann M, So CE, Argoff MK, et al.: Assessment: botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008, 70:1707\u20131714. This article reviews the medical literature on using BoNT for treating hypersecretory conditions as well as headache and other pain syndromes.","DOI":"10.1212\/01.wnl.0000311390.87642.d8"},{"key":"129_CR47","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/mus.21213","volume":"39","author":"CE Jackson","year":"2009","unstructured":"Jackson CE, Gronseth G, Rosenfeld J, et al.: Randomized double-blind study of botulinum toxin type B for sialorrhea in ALS patients. Muscle Nerve 2009, 39:137\u2013143.","journal-title":"Muscle Nerve"},{"key":"129_CR48","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.clineuro.2008.12.007","volume":"111","author":"AC Nobrega","year":"2009","unstructured":"Nobrega AC, Rodrigues B, Melo A: Does botulinum toxin injection in parotid glands interfere with the swallowing dynamics of Parkinson\u2019s disease patients? Clin Neurol Neurosurg 2009, 111:430\u2013432.","journal-title":"Clin Neurol Neurosurg"},{"key":"129_CR49","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1055\/s-0028-1112115","volume":"39","author":"B Wilken","year":"2008","unstructured":"Wilken B, Aslami B, Backes H: Successful treatment of drooling in children with neurological disorders with botulinum toxin A or B. Neuropediatrics 2008, 39:200\u2013204.","journal-title":"Neuropediatrics"},{"key":"129_CR50","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.pain.2006.09.012","volume":"125","author":"M Jakubowski","year":"2006","unstructured":"Jakubowski M, McAllister PJ, Bajwa ZH, et al.: Exploding vs imploding headache in migraine prophylaxis with Botulinum Toxin A. Pain 2006, 125:286\u2013295.","journal-title":"Pain"},{"key":"129_CR51","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/j.1526-4610.2005.05066.x","volume":"45","author":"NT Mathew","year":"2005","unstructured":"Mathew NT, Frishberg BM, Gawel M, et al.: Botulinum toxin type A (BOTOX) for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial. Headache 2005, 45:293\u2013307.","journal-title":"Headache"},{"issue":"Suppl 1","key":"129_CR52","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1046\/j.1526-4610.43.7s.3.x","volume":"43","author":"KR Aoki","year":"2003","unstructured":"Aoki KR: Evidence for antinociceptive activity of botulinum toxin type A in pain management. Headache 2003, 43(Suppl 1):S9\u2013S15.","journal-title":"Headache"},{"key":"129_CR53","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.pbb.2009.08.012","volume":"94","author":"L Bach-Rojecky","year":"2009","unstructured":"Bach-Rojecky L, Lackovic Z: Central origin of the antinociceptive action of botulinum toxin type A. Pharmacol Biochem Behav 2009, 94:234\u2013238.","journal-title":"Pharmacol Biochem Behav"},{"key":"129_CR54","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1471-4159.2009.05887.x","volume":"109","author":"M Caleo","year":"2009","unstructured":"Caleo M, Antonucci F, Restani L, Mazzocchio R: A reappraisal of the central effects of botulinum neurotoxin type A: by what mechanism? J Neurochem 2009, 109:15\u201324.","journal-title":"J Neurochem"}],"container-title":["Current Neurology and Neuroscience Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-010-0129-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11910-010-0129-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-010-0129-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,29]],"date-time":"2021-10-29T21:36:19Z","timestamp":1635543379000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11910-010-0129-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6,22]]},"references-count":54,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,9]]}},"alternative-id":["129"],"URL":"https:\/\/doi.org\/10.1007\/s11910-010-0129-z","relation":{},"ISSN":["1528-4042","1534-6293"],"issn-type":[{"value":"1528-4042","type":"print"},{"value":"1534-6293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,6,22]]}}}